About VectorY Therapeutics
VectorY Therapeutics is an Amsterdam-based biotech company developing vectorized antibody therapies for neurodegenerative diseases. Its approach uses AAV gene therapy to make neurons produce therapeutic antibodies themselves. The lead program, VTx-002, targets TDP-43 pathology in ALS and is in the Phase 1/2 PIONEER-ALS trial, which dosed its first participant in February 2026. A second program, VTx-003, targets Huntington's disease.
Founders
Jim Scibetta
CEO (since Dec 2024, not a founder)
Sander van Deventer
Co-founder, President of R&D (CEO Nov 2022 - Dec 2024)
Co-founder of VectorY, Amsterdam Molecular Therapeutics (now uniQure) and Forbion; involved in developing Remicade and Glybera.

- Biotech & Life Sciences
- Amsterdam, The Netherlands
- Series A
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| Series A | €74.5m | New: Angelini Ventures, Invest-NL, European Investment Bank; returning: Forbion, EQT Life Sciences, Eli Lilly and others | |
| Series A | €129.0m | EQT Life Sciences, Forbion |



